Business Finland, the government organization for innovation funding and trade, travel and investment promotion, has published a brochure on ‘World-class diagnostic innovations from Finland‘. The digital booklet showcases Finland’s strong capabilities in research, development &
Congratulations to Niklas for qualifying LS CancerDiag to the EIT Health Catapult semifinals! Introducing a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe.
Last month LS CancerDiag was selected as one of the 11 female-led start-ups to the EIT Health Women Entrepreneurship Bootcamp. The Women Entrepreneurship Bootcamp connects high growth, women-led or co-led start-ups to an unparalleled network
We are delighted to announce that LS CancerDiag has been selected as a participant to the EIT Health Bridgehead Europe programme! The Bridgehead programme provides European start-ups and scale-ups with individualised support in growing their validated
Even though it is the most common inherited cancer syndrome in the world, Lynch syndrome it largely unknown. In order to bring about change and improve awareness, March 22nd has been declared Lynch syndrome awareness
Today is International Women’s Day and we are proud to celebrate the achievements and contributions of all our female team members, without whom our company would quite simply not exist! It is still too rare
We are delighted to announce that Mariann Kasela has been appointed as Production Manager and will be responsible for the DiagMMR® production operations. Congratulations! Mariann has been with the company from the early days and
We are delighted to share our newly created video about Lynch syndrome and DiagMMR®! In this short 2-minute video we provide a summary of what Lynch syndrome is and how our newly developed functional assay
Business Finland, the government organization for innovation funding and trade, travel and investment promotion, has published a brochure on ‘Cancer Expertise from Finland’. The digital booklet showcases Finland as a global leader in cancer research
We are very happy that LS CancerDiag has been selected to be part of the first cohort of the X-Europe programme – HealthTech, MedTech and BioTech! LS CancerDiag is proud to have been selected from the
LS CancerDiag has launched a funding round in collaboration with Springvest.
The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.
